Rubella is a viral infection transmitted from person to person by droplets via coughs and sneezes. In healthy individuals it is usually a mild disease. Up to 50 % of individuals infected with rubella may not show symptoms. However, if a woman gets rubella shortly before getting pregnant or during the first three months of pregnancy, it is very likely to result in miscarriage or congenital anomalies known as congenital rubella syndrome (CRS).
ECDC promotes the performance of external quality assessment (EQA) schemes, in which laboratories are sent simulated clinical specimens or bacterial isolates for testing by routine or reference laboratory methods. EQA schemes, or laboratory proficiency testing, provide information about the accuracy of different characterisation and typing methods as well as antimicrobial susceptibility testing (AST) and the sensitivity of the methods in place to detect a certain pathogen or novel resistance patterns.
A vaccine is available which protects against the varicella virus; however policies on vaccine use vary across the EU. Varicella vaccination for all children is only recommended at national level in five countries (for the list of those countries see the ECDC vaccine scheduler). In most countries vaccination is available for adolescents without history of varicella and for the people who have higher risk of coming into contact with the varicella virus, like healthcare workers.